Literature DB >> 25471195

Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from a university teaching hospital in Japan.

Y Kuwata1, S Tanimoto, E Sawabe, M Shima, Y Takahashi, H Ushizawa, T Fujie, R Koike, N Tojo, T Kubota, R Saito.   

Abstract

Clostridium difficile infection control strategies require an understanding of its epidemiology. In this study, we analysed the toxin genotypes of 130 non-duplicate clinical isolates of C. difficile from a university hospital in Tokyo, Japan. Multilocus sequence typing (MLST) and eBURST analysis were performed for these isolates and nine strains previously analysed by polymerase chain reaction (PCR) ribotyping. Minimum inhibitory concentrations (MICs) were determined for six antibiotics, and the bacterial resistance mechanisms were investigated. Ninety-five toxigenic strains (73%), including seven tcdA-negative, tcdB-positive and cdtA/cdtB-negative strains (A(-)B(+)CDT(-)) and three A(+)B(+)CDT(+) strains, and 35 (27%) non-toxigenic strains, were classified into 23 and 12 sequence types, respectively. Of these, sequence type (ST)17 (21.8%) was the most predominant. MLST and eBURST analysis showed that 139 strains belonged to seven groups and singletons, and most A(+)B(+)CDT(-) strains (98%, 89/91) were classified into group 1. All isolates were susceptible to metronidazole, vancomycin and meropenem; the ceftriaxone, clindamycin and ciprofloxacin resistance rates were 49, 59 and 99%, respectively. Resistance rates to ceftriaxone and clindamycin were higher in toxigenic strains than in non-toxigenic strains (P < 0.001). All ST17 and ST81 strains were resistant to these antibiotics. The clindamycin- and fluoroquinolone-resistant strains carried erm(B) and mutations in GyrA and/or GyrB, respectively. To our knowledge, this is the first MLST-based study of the molecular epidemiology of toxigenic and non-toxigenic strains in Japan, providing evidence that non-toxigenic and toxigenic strains exhibit high genetic diversity and that toxigenic strains are more likely than non-toxigenic strains to exhibit multidrug resistance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25471195     DOI: 10.1007/s10096-014-2290-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  30 in total

1.  Comparative analysis of an expanded Clostridium difficile reference strain collection reveals genetic diversity and evolution through six lineages.

Authors:  Cornelis W Knetsch; Elisabeth M Terveer; Chris Lauber; Alexander E Gorbalenya; Céline Harmanus; Ed J Kuijper; Jeroen Corver; Hans C van Leeuwen
Journal:  Infect Genet Evol       Date:  2012-06-15       Impact factor: 3.342

2.  Identification of Clostridium difficile as a cause of pseudomembranous colitis.

Authors:  R H George; J M Symonds; F Dimock; J D Brown; Y Arabi; N Shinagawa; M R Keighley; J Alexander-Williams; D W Burdon
Journal:  Br Med J       Date:  1978-03-18

3.  Host range of the ermF rRNA methylase gene in bacteria of human and animal origin.

Authors:  W O Chung; C Werckenthin; S Schwarz; M C Roberts
Journal:  J Antimicrob Chemother       Date:  1999-01       Impact factor: 5.790

4.  Erythromycin resistance mutations in ribosomal proteins L22 and L4 perturb the higher order structure of 23 S ribosomal RNA.

Authors:  S T Gregory; A E Dahlberg
Journal:  J Mol Biol       Date:  1999-06-18       Impact factor: 5.469

5.  Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.

Authors:  Chun-Hsing Liao; Wen-Chien Ko; Jang-Jih Lu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

6.  Typing by sequencing the slpA gene of Clostridium difficile strains causing multiple outbreaks in Japan.

Authors:  Haru Kato; Toshiyuki Yokoyama; Yoshichika Arakawa
Journal:  J Med Microbiol       Date:  2005-02       Impact factor: 2.472

7.  Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates.

Authors:  F Barbut; P Mastrantonio; M Delmée; J Brazier; E Kuijper; I Poxton
Journal:  Clin Microbiol Infect       Date:  2007-09-11       Impact factor: 8.067

8.  Molecular analysis of Clostridium difficile at a university teaching hospital in Japan: a shift in the predominant type over a five-year period.

Authors:  E Sawabe; H Kato; K Osawa; T Chida; N Tojo; Y Arakawa; N Okamura
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-10       Impact factor: 3.267

9.  Association between PCR ribotypes and antimicrobial susceptibility among Clostridium difficile isolates from healthcare-associated infections in South Korea.

Authors:  Jieun Kim; Jung Oak Kang; Hyunjoo Pai; Tae Yeal Choi
Journal:  Int J Antimicrob Agents       Date:  2012-05-11       Impact factor: 5.283

10.  Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005.

Authors:  Marya D Zilberberg; Andrew F Shorr; Marin H Kollef
Journal:  Emerg Infect Dis       Date:  2008-06       Impact factor: 6.883

View more
  17 in total

Review 1.  Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection.

Authors:  Patrizia Spigaglia
Journal:  Ther Adv Infect Dis       Date:  2016-02

2.  Antimicrobial Susceptibilities of Clostridium difficile Isolates from 12 Asia-Pacific Countries in 2014 and 2015.

Authors:  Tanya Lew; Papanin Putsathit; Kyung Mok Sohn; Yuan Wu; Kentaro Ouchi; Yoshikazu Ishii; Kazuhiro Tateda; Thomas V Riley; Deirdre A Collins
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 3.  Antimicrobial resistance in Clostridioides difficile.

Authors:  Keeley O'Grady; Daniel R Knight; Thomas V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-08-24       Impact factor: 3.267

Review 4.  Double-Serine Fluoroquinolone Resistance Mutations Advance Major International Clones and Lineages of Various Multi-Drug Resistant Bacteria.

Authors:  Miklos Fuzi; Dora Szabo; Rita Csercsik
Journal:  Front Microbiol       Date:  2017-11-16       Impact factor: 5.640

5.  Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolates from two Korean hospitals.

Authors:  Asiimwe Nicholas; Yu Kyung Kim; Won-Kil Lee; Gati Noble Selasi; Seok Hyeon Na; Hyo Il Kwon; Yoo Jeong Kim; Hae Sook Lee; Kyung Eun Song; Jeong Hwan Shin; Je Chul Lee
Journal:  PLoS One       Date:  2017-03-29       Impact factor: 3.240

6.  Molecular epidemiology of Clostridium difficile in two tertiary care hospitals in Shandong Province, China.

Authors:  Ying Luo; Wen Zhang; Jing-Wei Cheng; Meng Xiao; Gui-Rong Sun; Cheng-Jie Guo; Ming-Jun Liu; Pei-Shan Cong; Timothy Kudinha
Journal:  Infect Drug Resist       Date:  2018-04-06       Impact factor: 4.003

Review 7.  The Epidemiology of Clostridium difficile Infection in Japan: A Systematic Review.

Authors:  Thomas V Riley; Tomomi Kimura
Journal:  Infect Dis Ther       Date:  2018-02-13

8.  The Role of Glutamate Dehydrogenase (GDH) Testing Assay in the Diagnosis of Clostridium difficile Infections: A High Sensitive Screening Test and an Essential Step in the Proposed Laboratory Diagnosis Workflow for Developing Countries like China.

Authors:  Jing-Wei Cheng; Meng Xiao; Timothy Kudinha; Zhi-Peng Xu; Lin-Ying Sun; Xin Hou; Li Zhang; Xin Fan; Fanrong Kong; Ying-Chun Xu
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

Review 9.  Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection.

Authors:  Simon D Baines; Mark H Wilcox
Journal:  Antibiotics (Basel)       Date:  2015-07-10

Review 10.  Dissimilar Fitness Associated with Resistance to Fluoroquinolones Influences Clonal Dynamics of Various Multiresistant Bacteria.

Authors:  Miklos Fuzi
Journal:  Front Microbiol       Date:  2016-07-07       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.